Lilly to buy Ventyx for $1.2B, bolstering oral inflammation pipeline
Lilly acquires Ventyx to expand oral inflammation pipeline.
Month: January 2026
NICE backs digital asthma tools for NHS use as evidence builds
The UK health watchdog National Institute for Health and Care Excellence (NICE) has recommended a suite of digital platforms to help people with asthma better manage their condition, signalling growing confidence in app-based tools as part of routine care, while stopping short of full endorsement pending further evidence. In draft guidance published yesterday, NICE said … Read more
IQWiG Highlights Evidence Gaps Despite Growing Treatment Options
Last week’s policy signals from Germany underscored a clear regulatory theme: access increasingly hinges on comparative evidence, not just innovation or unmet need. New assessments from the Institute for Quality and Efficiency in Health Care (IQWiG) highlighted where evidence is strong enough to support added benefit, where gaps remain despite growing treatment options. Multiple myeloma: … Read more
Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
Neuropulse Daily: January 8, 2026
Lilly in Advanced Talks to Acquire Ventyx Biosciences in Deal Valued Over $1B Pulse: Compass Pathways Partners With Radial to Shape Psilocybin Care Delivery Pulse: Bial Launches KYNMOBI in the UK for Parkinson’s OFF Episodes Pulse: NeuraLight Completes Landmark Parkinson’s Biomarker Trial Pulse: EA Pharma Initiates Phase 3 Evenamide Trial in Schizophrenia Pulse: Rapport Therapeutics … Read more
Lilly in advanced talks to buy Ventyx in a deal topping $1B
Eli Lilly is in advanced talks to acquire Ventyx Biosciences for more than $1B, a move that would add inflammatory bowel disease and neurology assets.
Lilly Reups With Nimbus in $1.3B Oral Obesity Deal
Eli Lilly has signed a new collaboration with Nimbus Therapeutics worth up to $1.3B to develop a novel oral obesity drug.
NeuroPulse Daily January 7, 2026
VB Spine Completes Acquisition of Stryker’s Cestas Manufacturing Facility Pulse: Anavex Receives Constructive FDA Feedback on Alzheimer’s Disease Program Pulse: Newleos Therapeutics Doses First Patient in Phase 2 SOAR Study for Social Anxiety Disorder Pulse: Lysoway Therapeutics Advances LW-1017 to Phase I Readiness in Neurodegeneration Pulse: LoQus23 Nominates LQT-23 as First-in-Class Oral Drug Candidate for … Read more
Ikarovec Eyes $1B Deal to Move Eye Gene Therapy In-Office
UK biotech Ikarovec teams with VectorBuilder on eye gene delivery.
NeuroPulse Daily: January 05, 2026
Daily neurology update covering Alzheimer’s, Parkinson’s, epilepsy, ADHD.